TMDX logo

TMDX

TransMedics Group Inc.

$130.93
+$7.11(+5.74%)
55
Overall
20
Value
90
Tech
--
Quality
Market Cap
$4.17B
Volume
910.34K
52W Range
$55.00 - $145.50
Target Price
$141.64

Company Overview

Mkt Cap$4.17BPrice$130.93
Volume910.34KChange+5.74%
P/E Ratio117.7Open$123.39
Revenue$441.5MPrev Close$123.82
Net Income$35.5M52W Range$55.00 - $145.50
Div YieldN/ATarget$141.64
Overall55Value20
Quality--Technical90

No chart data available

About TransMedics Group Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Sector: Healthcare
Industry: Medical Devices

Latest News

Oppenheimer Remains a Buy on TransMedics Group (TMDX)

Oppenheimer analyst Suraj Kalia maintained a Buy rating on TransMedics Group today and set a price target of $150.00. The company’s shares opened t...

TipRanks Auto-Generated Intelligence Newsdesk20 days ago

TransMedics Group’s Earnings Call Highlights Robust Growth and Strategic Expansion

TipRanks Auto-Generated Newsdesk23 days ago

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS)

Catie Powers24 days ago

TransMedics Group Reports Strong Q3 2025 Results

TipRanks Auto-Generated Newsdesk24 days ago

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

TipRanks Auto-Generated Intelligence Newsdeska month ago
ABCD
1SymbolPriceChangeVol
2TMDX$130.93+5.7%910.34K
3
4
5
6

Get TransMedics Group Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.